Thursday, January 10, 2019 12:02:39 PM
Now the big question here is, does taking the fat tissue and processing it through centrifuge and enzymes warrant the adipose tissue for cells to be characterized as a “Drug” and in turn be under FSA regulation. The FDA has guidance documents which say their opinion is that these treatments should fall under the “drug” category however this is only guidance. The FDA director Gotlieb
Said himself we are in a “paradigm shift” in modern medicine with regenerative stem cell therapy, however it seems they want more control over this based on the recent lawsuit. Through mediation we may find out what is the fair approach here, otherwise it would go to trial of our peers. Ask yourself this....if you took random people off the street and asked them “should their own cells in their bodies be regulated by the FDA”. IMO the overwhelming response would be a big NO.
I think the DOJ/FDA realize if this goes to trial USRM’s chances of outright winning are extremely high. IMO the DOJ/FDA will take a “meet in the middle approach” in mediation to try and get some semblance of control/oversight. If not and USRM holds their ground, then good for USRM and people’s right to harness their own bodies to heal. I like their chances in a trial of peers. Downside here is 100% if USRM is shut down but there is infinite upside. Bottom line...if there was a legal way to shut them down it would have already happened, this is a control/oversight issue and one would be foolish to not think Big Pharma may be playing a role in holding these ground breaking therapies back as long as they can.
All just my opinion here folks
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM